| 効果 | 減少 |
| 試験方法 | コホート法 |
| 試験期間 | 1-6 ヶ月 |
| 被験者数 | 10 |
| 性別 | 不明 |
この研究の注釈：
6g of supplementation (77% CLA by weight; 1:1 ratio of the two main isomers) for 12 weeks noted significant improvements in quality of life () associated with supplementation (pilot study, no placebo group). The benefit seen according to CDAI rating was 13.1% at week 6 and 23.6% at 12 weeks with the authors suggesting that it may not be clinically significant.
6g of supplementation (77% CLA by weight; 1:1 ratio of the two main isomers) for 12 weeks noted significant improvements in quality of life () associated with supplementation (pilot study, no placebo group). The benefit seen according to CDAI rating was 13.1% at week 6 and 23.6% at 12 weeks with the authors suggesting that it may not be clinically significant.
Secretion of IL-2 increased from isolated CD4+ and CD8+ lymphocytes, while serum IL-6 was higher after 12 weeks. IL-8, IL-1β, IL-10, TNF-α, or IL-12p70 were all unaffected, and lymphocyte secretion of TNF-α and IFNy was reduced.
